Atopic Dermatitis (Eczema) clinical trials at UCSF
5 in progress, 3 open to eligible people
Immunogenetic Profiling of Dupilumab for the Treatment of Atopic Dermatitis
open to eligible people ages 18 years and up
This is a single-arm, open-label study to examine the effect of dupilumab on the immunologic and genetic environment within atopic dermatitis skin lesions.
San Francisco, California
Long-term Safety and Efficacy of Nemolizumab With Moderate-to-severe Atopic Dermatitis
open to eligible people ages 12 years and up
Long-Term Safety and Efficacy of Nemolizumab in Subjects with Moderate-to-Severe Atopic Dermatitis Description
San Francisco, California and other locations
The Impact of Dupilumab on Quality of Life in Moderate to Severe Atopic Dermatitis Patients
open to eligible people ages 18 years and up
This is a single-arm, open-label study, which will examine the effect of dupilumab on quality of life in atopic dermatitis patients.
San Francisco, California
Open-Label Extension Study of Upadacitinib in Adult Participants With Moderate to Severe Atopic Dermatitis
Sorry, in progress, not accepting new patients
This is a study for adults (18-75 years) who have successfully completed treatment either with Dupilumab or with Upadacitinib in the study M16-046. At the end of M16-046, they have the option to receive Upadacitinib with a duration of 52 weeks beyond the timeframe of Study M16-046. There will be a 30 day follow-up visit after the treatment period is completed. Main objective of this study is to assess long-term safety, tolerability and efficacy of upadacitinib in participants with moderate to severe atopic dermatitis who successfully completed treatment in the study M16-046.
Fresno, California and other locations
Skin Tracker: A Mobile Health App to Monitor Skin Disease Activity and Treatment Use
Sorry, not yet accepting patients
Design and beta-test a research-oriented mobile health app to assess disease activity, quality of life, treatment patterns, adverse medication effects, and lifestyle factors in patients with atopic dermatitis.
San Francisco, California
Last updated: